SCHEMBL9966868

SCHEMBL9966868

Brc1ccc2oc(-c3ccccc3)nc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.66
NPC1 O15118 8/20 0.66
RAB9A P51151 8/20 0.66
KDM4E B2RXH2 6/20 0.66
HPGD P15428 3/20 0.66
CASP3 P42574 2/20 0.66
SENP7 Q9BQF6 2/20 0.66
SENP6 Q9GZR1 2/20 0.66
POLB P06746 2/20 0.66
SENP8 Q96LD8 1/20 0.66
MAPT P10636 4/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
TP53 P04637 3/20 0.61
HSD17B10 Q99714 2/20 0.61
HDAC6 Q9UBN7 3/20 0.58
ALDH1A1 P00352 3/20 0.54
PTPN2 P17706 3/20 0.52
PTPN1 P18031 3/20 0.52
PTPN5 P54829 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29407356 1.00 SMN1; SMN2 (0.66) SMN1; SMN2NPC1RAB9AKDM4EHPGD
SCHEMBL25498923 0.97 SMN1; SMN2 (0.62) SMN1; SMN2NPC1RAB9AKDM4EHPGD
SCHEMBL10173054 0.89 HDAC6 (0.64) SMN1; SMN2NPC1RAB9AKDM4EHPGD
SCHEMBL2139699 0.86 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AKDM4EHPGD
SCHEMBL1026557 0.85 PIK3CB (0.67) SMN1; SMN2NPC1RAB9AKDM4EHPGD
SCHEMBL29780606 0.85 PIK3CB (0.67) SMN1; SMN2NPC1RAB9AKDM4EHPGD
SCHEMBL3722175 0.84 TP53 (0.61) SMN1; SMN2NPC1RAB9AKDM4EHPGD
SCHEMBL13528498 0.84 NPC1 (0.72) SMN1; SMN2NPC1RAB9AKDM4EHPGD
SCHEMBL2247467 0.83 RAB9A (0.76) SMN1; SMN2NPC1RAB9AKDM4EHPGD
SCHEMBL11382720 0.83 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240237514-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER LT MATERIALS CO., LTD. (KR) 2024-07-11 US disclosed
US-20240237514-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER LT MATERIALS CO., LTD. (KR) 2024-07-11 US disclosed
EP-4063368-B1 NITROGEN-CONTAINING COMPOUND AND ELECTRONIC ELEMENT COMPRISING SAME, AND ELECTRONIC APPARATUS SHAANXI LIGHTE OPTOELECTRONICS MAT CO LTD (CN) 2024-06-26 EP disclosed
CN-118165007-A Condensed ring compound, application thereof and organic electroluminescent device 北京绿人科技有限责任公司 2024-06-11 CN disclosed
CN-113972332-B Organic electroluminescent device and electronic device including the same 陕西莱特光电材料股份有限公司 2024-05-24 CN disclosed
CN-114933595-B 2-Phenylbenzoxazole multi-stimulus response fluorescent material and preparation method thereof 长春工业大学 2024-04-30 CN disclosed
EP-4324831-A1 ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS Shaanxi Lighte Optoelectronics Material Co., Ltd. (CN) 2024-02-21 EP disclosed
WO-2023172110-A1 COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME 주식회사 엘지화학 2023-09-14 WO disclosed
WO-2023172110-A1 COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME 주식회사 엘지화학 2023-09-14 WO disclosed
US-20230217814-A1 ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2023-07-06 US disclosed
US-10889901-B2 Ultraviolet-stabilized corrosion inhibitors INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2021-01-12 US disclosed
CN-112028853-A Arylamine derivative and organic electroluminescent device thereof 长春海谱润斯科技股份有限公司 2020-12-04 CN disclosed
US-20200032401-A1 ULTRAVIOLET-STABILIZED CORROSION INHIBITORS INTERNATIONAL BUSINESS MACHINES CORPORATION 2020-01-30 US disclosed
WO-2018043913-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME 주식회사 두산 2018-03-08 WO disclosed
WO-2015111943-A1 ORGANIC COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME 주식회사 두산 2015-07-30 WO disclosed
WO-2015111943-A1 ORGANIC COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME 주식회사 두산 2015-07-30 WO disclosed
US-9006450-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-14 US disclosed
US-9006450-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-14 US disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10889901-B2 Ultraviolet-stabilized corrosion inhibitors TYR, UNG, MGMT SMN1; SMN2 3108/4885NPC1 4864/4885RAB9A 2203/4885
US-20200032401-A1 ULTRAVIOLET-STABILIZED CORROSION INHIBITORS TYR, UNG, MGMT SMN1; SMN2 3108/4885NPC1 4864/4885RAB9A 2203/4885
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF P2RX5, P2RX3, ABCG2 SMN1; SMN2 4388/4885NPC1 350/4885RAB9A 2252/4885
US-20230217814-A1 ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME AOX1, XDH, PPOX SMN1; SMN2 4240/4885NPC1 1470/4885RAB9A 3117/4885
US-20240237514-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER CYP1A1, CYP1B1, CYP2E1 SMN1; SMN2 3276/4885NPC1 1364/4885RAB9A 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.